Seek Returns

MEDP vs. RVTY: Medpace vs. Revvity Stock Comparison

How do Medpace (MEDP) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Medpace (MEDP) and Revvity (RVTY) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Medpace (MEDP) and Revvity (RVTY)
Profile ItemMEDPRVTY
NameMedpace Holdings, Inc.Revvity Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
Market Capitalization18.27 billion USD17.31 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateAugust 11, 2016February 21, 1973
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

MEDP
RVTY
GSPC
Loading price history…
Medpace (MEDP) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Medpace (MEDP) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Medpace (MEDP) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Medpace (MEDP) and Revvity (RVTY)
MetricMEDPRVTY
Total Return (1Y)13.29%76.75%
Total Return (3Y, Annualized)35.26%24.22%
Total Return (5Y, Annualized)24.49%-1.48%

Risk Profile

Drawdown History

MEDP
RVTY
GSPC
Loading price history…
Medpace (MEDP) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Medpace (MEDP) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Medpace (MEDP) and Revvity (RVTY)
MetricMEDPRVTY
Volatility (1Y, Annualized)44.16%40.22%
Beta (5Y)1.101.07
Max Drawdown (5Y)-42.87%-59.01%
Avg. Volume (3M)258.39K1.89M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
MEDP and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Medpace (MEDP) and Revvity (RVTY)
MetricMEDPRVTY
Sharpe Ratio (1Y)0.201.80
Sortino Ratio (1Y)0.262.90

Profitability

ROE (TTM)

Medpace (MEDP) at 117.88% clears its industry range for ROE, a sharper capital-efficiency signal than Revvity (RVTY) at 3.45%, which is closer to a typical peer reading.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP
117.88%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max
109.18%
Q3
6.23%
RVTY
3.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Medpace (MEDP) at 18.24% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP
18.24%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max
18.05%
RVTY
8.61%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Medpace (MEDP) at 23.12% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max
83.12%
MEDP
23.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max
83.12%
RVTY
17.06%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Medpace (MEDP) and Revvity (RVTY)
MetricMEDPRVTY
ROE (TTM)117.88%3.45%
ROA (TTM)18.71%2.54%
Net Margin (TTM)18.24%8.61%
Operating Margin (TTM)23.12%17.06%
Gross Margin (TTM)72.24%55.91%

Growth

Revenue Growth

Both Medpace (MEDP) at 19.97% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Medpace (MEDP) at 20.98% and Revvity (RVTY) at -5.91% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Medpace (MEDP) and Revvity (RVTY)
MetricMEDPRVTY
Revenue Growth (YoY)19.97%3.67%
Revenue Growth (3Y CAGR)20.12%-4.82%
EPS Growth (YoY)20.98%-5.91%
EPS Growth (3Y CAGR)28.04%-23.26%

Financial Strength

Current Ratio (MRQ)

Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
MEDP
0.83
Min
0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max
25.13
Q3
12.13
Median
5.52
RVTY
2.65
Q1
2.47
Min
0.10
Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Medpace (MEDP) at 0.29 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max
1.42
Q3
0.65
MEDP
0.29
Median
0.15
Q1
0.02
Min
0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
RVTY
0.38
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Medpace (MEDP) and Revvity (RVTY)
MetricMEDPRVTY
Current Ratio (MRQ)0.832.65
Debt / Equity (MRQ)0.290.38
Net Debt / EBITDA-0.842.43

Dividends

Dividend Yield (TTM)

Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY
0.19%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY
13.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Medpace (MEDP) and Revvity (RVTY)
MetricMEDPRVTY
Dividend Yield (TTM)0.00%0.19%
Dividend Payout Ratio (TTM)0.00%13.40%

Valuation

P/E Ratio (TTM)

Medpace (MEDP) at 36.26 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max
85.34
Q3
43.46
MEDP
36.26
Median
26.69
Q1
13.30
Min
0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max
85.34
RVTY
68.94
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Medpace (MEDP) at 6.44 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max
58.18
Q3
25.77
Median
7.30
MEDP
6.44
Q1
3.01
Min
0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max
58.18
Q3
25.77
Median
7.30
RVTY
5.88
Q1
3.01
Min
0.01
Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Revvity (RVTY) at 2.39 sits near its industry’s typical P/B ratio, while Medpace (MEDP) at 31.23 prices above its benchmark range — MEDP looks rich relative to book.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP
31.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max
13.53
Q3
6.54
Median
3.25
RVTY
2.39
Q1
1.69
Min
-5.59
Loading chart…
Medpace (MEDP) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Medpace (MEDP) and Revvity (RVTY)
MetricMEDPRVTY
P/E Ratio (TTM)36.2668.94
P/S Ratio (TTM)6.445.88
P/B Ratio (MRQ)31.232.39
Free Cash Flow Yield (TTM)2.72%3.62%